BeyondSpring 10-Q Flags Going Concern Doubt and Lilly Collaboration End
BYSI is trading near its 52-week low of $0.73 (12% above the low).
Summary
BeyondSpring's 10-Q discloses going concern doubt and the termination of its Eli Lilly collaboration, adding significant risk to the investment thesis.
Key Events · Earnings and Guidance · BYSI
-
Going Concern Doubt
The company states substantial doubt about its ability to continue as a going concern, with $4.3M net current liabilities and $6.5M cash and short-term investments as of June 30, 2026.
-
Lilly Collaboration Terminated
Eli Lilly gave notice to end the research collaboration effective August 20, 2026. SEED retains rights to collaboration targets and inventions, but no new agreement is assured.
-
Cash Runway Pressure
Continuing operations used $7.0M in operating cash during H1 2026, leaving $2.7M cash and $3.8M short-term investments at quarter end.
-
CEO Employment Terms
New CEO Min Qiu's agreement includes $100,000 annual salary, 30% bonus target, 100,000 stock options, and 9-month severance upon qualifying termination.
Analysis · BYSI · Life Sciences
BeyondSpring's Q2 10-Q reveals substantial doubt about its ability to continue as a going concern, with only $6.5 million in cash and short-term investments against $4.3 million in net current liabilities. The company also disclosed that Eli Lilly is terminating its research collaboration effective August 20, 2026, removing a key validation and potential milestone revenue stream. These are material new disclosures beyond the earnings press release issued earlier today.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 984 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.83%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BYSI was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $0.73 to $2.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.